About Thallion Pharmaceuticals
Thallion Pharmaceuticals is a Healthcare company based in Dorval (Canada) founded in 2007, and was acquired by Taro in March 2017. Therapeutics for STEC bacterial infections are developed. Its focus areas include Life Sciences, Immunotherapy, Antibody and Disease-Targeting.
Company details
Thallion Pharmaceuticals was founded in 2007 in Dorval, Canada, and operates within the biotechnology sector focused on infectious diseases. Therapeutics targeting Shigatoxin-producing E. coli infections are developed, with Shigamabs serving as the primary antibody-based product candidate. As of June 2013, the company has functioned as a subsidiary of Bellus Health, emphasizing treatments for bacterial infections through antibody and small molecule approaches.
- Headquarters Dorval, Canada
- Stage Acquired
- SectorsHealthcare
- Website thallion.com
- Social LinkedIn
- Acquired by Taro (Mar 2017)
- Investors
- Acquired byTaro
(Mar 2017)
Investors in Thallion Pharmaceuticals
Thallion Pharmaceuticals has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Taro Pharmaceutical Industries.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Taro Pharmaceutical Industries is engaged in developing and distributing pharmaceuticals. | 1950 | taro.com | Haifa, Israel |
Investor details for Thallion Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Thallion Pharmaceuticals
2 dated milestones of Thallion Pharmaceuticals across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Thallion Pharmaceuticals is founded.
- Exit Acquired by Taro.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Thallion Pharmaceuticals
Complete news archive for Thallion Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Thallion Pharmaceuticals
Thallion Pharmaceuticals was founded in 2007.
Thallion Pharmaceuticals is headquartered in Dorval, Canada. It is registered at Dorval, Quebec, Canada.
Thallion Pharmaceuticals was founded in 2007 in Dorval, Canada, and operates within the biotechnology sector focused on infectious diseases. Therapeutics targeting Shigatoxin-producing E. coli infections are developed, with Shigamabs serving as the primary antibody-based product candidate. As of June 2013, the company has functioned as a subsidiary of Bellus Health, emphasizing treatments for bacterial infections through antibody and small molecule approaches.
Thallion Pharmaceuticals has 1 investor. Key investors include Taro Pharmaceutical Industries.
Yes. Thallion Pharmaceuticals was acquired by Taro in March 2017.